Business Wire

Orca Bio to Present Clinical Data on Its High-Precision Cell Therapies at the 66th American Society of Hematology Annual Meeting

Long-term survival data with Orca-T will be presented for the first time in patients with AML, ALL and MDS Early feasibility data on the combination of Orca-T and an allogeneic CAR-T in patients with ...
FiercePharma

Orca rides $250M funding wave toward cancer cell therapy launch

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy. California-based Orca filed for FDA ...
FierceBiotech

Orca's cell therapy trounces traditional care in blood cancer phase 3, swimming into space's 'holy grail'

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the rate at which patients survived without developing chronic ...
Business Wire

Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting

– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing myeloablative conditioning as seen in younger patients across disease control ...